Article info

Download PDFPDF

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Authors

  1. Correspondence to Dr Toby M Maher; t.maher{at}rbht.nhs.uk
View Full Text

Citation

Maher TM, Kreuter M, Lederer DJ, et al
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Publication history

  • Received February 21, 2019
  • Revised April 23, 2019
  • Accepted May 2, 2019
  • First published May 21, 2019.
Online issue publication 
May 21, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.